Curevac N v
Officers & Directors
Alexander Zehnder, MD, MBA, age 55, has served as Chief Executive Officer since April 2023. He has over 20 years of pharmaceutical industry experience in Europe, the US, and Japan, including roles as Global Head of Oncology at Sanofi and Vice President at Roche/Genentech. He holds a Medical Doctor degree from the University of Bern and an MBA from IMD Business School.
Axel Sven Malkomes, age 58, joined as Chief Financial Officer in November 2024. He has over 30 years of senior corporate and investment banking experience in biotech and pharma. His previous positions include CFO at Cardior Pharmaceuticals and Medigene AG, as well as roles at Barclays, Société Générale, 3i Group plc, and Merck KGaA. He holds a business administration degree from Otto-Friedrich University and completed executive programs at INSEAD, Kellogg School of Management, and Hong Kong University of Science and Technology.
Myriam Mendila, MD, age 59, has been Chief Scientific Officer since February 2023. She has over 20 years of global experience in product development, medical affairs, pharmacovigilance, healthcare compliance, and global product strategy at Roche, Genentech, and Novartis. She previously served as Worldwide Head of Medical Affairs and Chief Medical Officer Oncology at Novartis Pharma AG, Switzerland.
Curevac N v currently has 370 employees.
|
